Altimmune said it is intensifying early-stage liver disease research, deploying cross-functional teams to speed development of new therapies. The push comes as

Altimmune said it is intensifying early-stage liver disease research, deploying cross-functional teams to speed development of new therapies. The push comes as the biotech advances its Phase 3 PERFORMA trial in MASH and updates investors on Q2 2026 results.